Drug intelligence / Profile preview

QG101-23-0

Development stage: Unknown
Lead developer: Amckaus
Modality: Small Molecules
Administration: Oral

Overview

QG101-23-0 is an investigational small molecule drug currently in Phase 1 clinical trials. It is being evaluated for its safety, tolerability, and pharmacokinetics in healthy volunteers through single ascending dose (SAD) and multiple ascending dose (MAD) studies. The drug is administered orally as capsules. As of now, the specific mechanism of action and therapeutic indication have not been disclosed publicly. The developer of QG101-23-0 is Amckaus PTY LTD.

Beyond the preview

Go deeper on QG101-23-0.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QG101-23-0.

Explore the full profile